NasdaqCM - Nasdaq Real Time Price USD

Intensity Therapeutics, Inc. (INTS)

0.4200
-0.0800
(-16.00%)
At close: May 16 at 4:00:02 PM EDT
0.4300
+0.01
+(2.38%)
After hours: May 16 at 7:58:33 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for INTS

Recent News: INTS

View More
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR Newswire 3 days ago
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France
PR Newswire 11 days ago
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering
PR Newswire 22 days ago
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?

Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Zacks 26 days ago
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?

Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?
Zacks last month
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
PR Newswire 2 months ago
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
PR Newswire 3 months ago
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
PR Newswire 4 months ago
Intensity Therapeutics reports positive results of INT230-6 in breast cancer

Intensity Therapeutics reports positive results of INT230-6 in breast cancer
TipRanks 5 months ago

Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial
PREMIUM
MT Newswires 5 months ago
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
PR Newswire 5 months ago
View More

Related Tickers

WINT Windtree Therapeutics, Inc.
0.8280
-0.24%
 
ENTO Entero Therapeutics, Inc.
0.4243
-1.33%
 
MTVA MetaVia Inc.
0.6845
+1.29%
 
SPRB Spruce Biosciences, Inc.
0.0650
+0.15%
 
SCNI Scinai Immunotherapeutics Ltd.
2.9100
+5.43%
 
TOVX Theriva Biologics, Inc.
0.5588
+3.27%
 
RLMD Relmada Therapeutics, Inc.
0.4610
+11.51%
 
KAPA Kairos Pharma, Ltd.
0.6210
+0.98%
 
FHTX Foghorn Therapeutics Inc.
4.4300
+2.78%
 
VOR Vor Biopharma Inc.
0.1769
+3.51%